These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 27209210

  • 21. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.
    J Ovarian Res; 2017 Feb 10; 10(1):9. PubMed ID: 28187748
    [Abstract] [Full Text] [Related]

  • 22. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Silva R, Glennon K, Metoudi M, Moran B, Salta S, Slattery K, Treacy A, Martin T, Shaw J, Doran P, Lynch L, Jeronimo C, Perry AS, Brennan DJ.
    Int J Cancer; 2023 Jul 01; 153(1):120-132. PubMed ID: 36883413
    [Abstract] [Full Text] [Related]

  • 23. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.
    Clin Cancer Res; 2004 Oct 01; 10(19):6432-6. PubMed ID: 15475429
    [Abstract] [Full Text] [Related]

  • 24. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.
    J Clin Oncol; 2007 Feb 10; 25(5):517-25. PubMed ID: 17290060
    [Abstract] [Full Text] [Related]

  • 25. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.
    Cancer; 2019 Aug 15; 125(16):2772-2781. PubMed ID: 31154673
    [Abstract] [Full Text] [Related]

  • 26. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ.
    Gynecol Oncol; 2009 Jul 15; 114(1):48-52. PubMed ID: 19361839
    [Abstract] [Full Text] [Related]

  • 27. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.
    Roy M, Connor J, Al-Niaimi A, Rose SL, Mahajan A.
    Hum Pathol; 2018 Mar 15; 73():1-6. PubMed ID: 28851663
    [Abstract] [Full Text] [Related]

  • 28. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    Lancet Oncol; 2015 Jan 15; 16(1):87-97. PubMed ID: 25481791
    [Abstract] [Full Text] [Related]

  • 29. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
    Sallum LF, Andrade L, Bastos Eloy da Costa L, Ramalho S, Ferracini AC, Natal RA, Brito ABC, Sarian LO, Derchain S.
    Int J Gynecol Cancer; 2018 Mar 15; 28(3):437-447. PubMed ID: 29465506
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L, Wang H, Li P.
    Invest New Drugs; 2018 Apr 15; 36(2):187-194. PubMed ID: 29082457
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.
    Eur J Cancer; 2016 Jan 15; 53():51-64. PubMed ID: 26693899
    [Abstract] [Full Text] [Related]

  • 34. TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Montemorano L, Shultz ZB, Farooque A, Hyun M, Chappell RJ, Hartenbach EM, Lang JD.
    Gynecol Oncol; 2024 Jul 15; 186():26-34. PubMed ID: 38555766
    [Abstract] [Full Text] [Related]

  • 35. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
    Lee M, Nam EJ, Kim SW, Kim S, Kim JH, Kim YT.
    Int J Gynecol Cancer; 2012 Nov 15; 22(9):1489-96. PubMed ID: 23095773
    [Abstract] [Full Text] [Related]

  • 36. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer.
    Pant AC, Diaz-Montes T, Tanner E, Ahmad S, Giuntoli RL, Holloway RW, Bristow RE.
    J Chemother; 2010 Aug 15; 22(4):270-4. PubMed ID: 20685633
    [Abstract] [Full Text] [Related]

  • 37. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.
    Oncology; 2013 Aug 15; 84(3):158-65. PubMed ID: 23296063
    [Abstract] [Full Text] [Related]

  • 38. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug 15; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 39. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO.
    Anticancer Res; 2006 Aug 15; 26(1B):687-93. PubMed ID: 16739339
    [Abstract] [Full Text] [Related]

  • 40. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
    Mariya T, Hirohashi Y, Torigoe T, Asano T, Kuroda T, Yasuda K, Mizuuchi M, Sonoda T, Saito T, Sato N.
    Cancer Immunol Res; 2014 Dec 15; 2(12):1220-9. PubMed ID: 25324403
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.